Selected research
Market Analysis & Forecast
Global Pharmacology Discovery Service Market Analysis and Forecast 2026-2032
Market perspective
The global Pharmacology Discovery Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Pharmacology Discovery Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Pharmacology Discovery Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Pharmacology Discovery Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Pharmacology Discovery Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Pharmacology Discovery Service include Ichor Life Sciences, Inc, NUVISAN, Porsolt, Charles River Laboratories, Eurofins Discovery, Labcorp, BioDuro-Sundia, Creative Biolabs and BRF, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Pharmacology Discovery Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Pharmacology Discovery Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Pharmacology Discovery Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pharmacology Discovery Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pharmacology Discovery Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pharmacology Discovery Service revenue, projected growth trends, production technology, application and end-user industry.
Pharmacology Discovery Service Segment by Company
Ichor Life Sciences, Inc
NUVISAN
Porsolt
Charles River Laboratories
Eurofins Discovery
Labcorp
BioDuro-Sundia
Creative Biolabs
BRF
WuXi AppTec
Dalriada
Sygnature Discovery
Pharmaron
ChemPartner
NuChem Sciences Inc
Genscript ProBio
Pharmacology Discovery Service Segment by Type
In Vivo Disease Model
Cell Based Assays Service
Drug Discovery Service
Others
Pharmacology Discovery Service Segment by Application
Cardiovascular Disease
Eye Diseases
Autoimmune Diseases
Musculoskeletal Diseases
Other
Pharmacology Discovery Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacology Discovery Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharmacology Discovery Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacology Discovery Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Pharmacology Discovery Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Pharmacology Discovery Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmacology Discovery Service revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- In Vivo Disease Model
- Cell Based Assays Service
- Drug Discovery Service
- Others
Applications
- Cardiovascular Disease
- Eye Diseases
- Autoimmune Diseases
- Musculoskeletal Diseases
- Other
Companies covered
- Ichor Life Sciences, Inc
- NUVISAN
- Porsolt
- Charles River Laboratories
- Eurofins Discovery
- Labcorp
- BioDuro-Sundia
- Creative Biolabs
- BRF
- WuXi AppTec
- Dalriada
- Sygnature Discovery
- Pharmaron
- ChemPartner
- NuChem Sciences Inc
- Genscript ProBio
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Pharmacology Discovery Service Market by Type
- 1.2.1 Global Pharmacology Discovery Service Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 In Vivo Disease Model
- 1.2.3 Cell Based Assays Service
- 1.2.4 Drug Discovery Service
- 1.2.5 Others
- 1.3 Pharmacology Discovery Service Market by Application
- 1.3.1 Global Pharmacology Discovery Service Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Cardiovascular Disease
- 1.3.3 Eye Diseases
- 1.3.4 Autoimmune Diseases
- 1.3.5 Musculoskeletal Diseases
- 1.3.6 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Pharmacology Discovery Service Market Dynamics
- 2.1 Pharmacology Discovery Service Industry Trends
- 2.2 Pharmacology Discovery Service Industry Drivers
- 2.3 Pharmacology Discovery Service Industry Opportunities and Challenges
- 2.4 Pharmacology Discovery Service Industry Restraints
3 Global Growth Perspective
- 3.1 Global Pharmacology Discovery Service Market Perspective (2021-2032)
- 3.2 Global Pharmacology Discovery Service Growth Trends by Region
- 3.2.1 Global Pharmacology Discovery Service Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Pharmacology Discovery Service Market Size by Region (2021-2026)
- 3.2.3 Global Pharmacology Discovery Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Pharmacology Discovery Service Revenue by Players
- 4.1.1 Global Pharmacology Discovery Service Revenue by Players (2021-2026)
- 4.1.2 Global Pharmacology Discovery Service Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Pharmacology Discovery Service Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Pharmacology Discovery Service Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Pharmacology Discovery Service Key Players Headquarters & Area Served
- 4.4 Global Pharmacology Discovery Service Players, Product Type & Application
- 4.5 Global Pharmacology Discovery Service Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Pharmacology Discovery Service Market CR5 and HHI
- 4.6.3 2025 Pharmacology Discovery Service Tier 1, Tier 2, and Tier 3
5 Pharmacology Discovery Service Market Size by Type
- 5.1 Global Pharmacology Discovery Service Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Pharmacology Discovery Service Revenue by Type (2021-2032)
- 5.3 Global Pharmacology Discovery Service Revenue Market Share by Type (2021-2032)
6 Pharmacology Discovery Service Market Size by Application
- 6.1 Global Pharmacology Discovery Service Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Pharmacology Discovery Service Revenue by Application (2021-2032)
- 6.3 Global Pharmacology Discovery Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Ichor Life Sciences, Inc
- 7.1.1 Ichor Life Sciences, Inc Company Information
- 7.1.2 Ichor Life Sciences, Inc Business Overview
- 7.1.3 Ichor Life Sciences, Inc Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.1.4 Ichor Life Sciences, Inc Pharmacology Discovery Service Product Portfolio
- 7.1.5 Ichor Life Sciences, Inc Recent Developments
- 7.2 NUVISAN
- 7.2.1 NUVISAN Company Information
- 7.2.2 NUVISAN Business Overview
- 7.2.3 NUVISAN Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.2.4 NUVISAN Pharmacology Discovery Service Product Portfolio
- 7.2.5 NUVISAN Recent Developments
- 7.3 Porsolt
- 7.3.1 Porsolt Company Information
- 7.3.2 Porsolt Business Overview
- 7.3.3 Porsolt Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.3.4 Porsolt Pharmacology Discovery Service Product Portfolio
- 7.3.5 Porsolt Recent Developments
- 7.4 Charles River Laboratories
- 7.4.1 Charles River Laboratories Company Information
- 7.4.2 Charles River Laboratories Business Overview
- 7.4.3 Charles River Laboratories Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.4.4 Charles River Laboratories Pharmacology Discovery Service Product Portfolio
- 7.4.5 Charles River Laboratories Recent Developments
- 7.5 Eurofins Discovery
- 7.5.1 Eurofins Discovery Company Information
- 7.5.2 Eurofins Discovery Business Overview
- 7.5.3 Eurofins Discovery Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.5.4 Eurofins Discovery Pharmacology Discovery Service Product Portfolio
- 7.5.5 Eurofins Discovery Recent Developments
- 7.6 Labcorp
- 7.6.1 Labcorp Company Information
- 7.6.2 Labcorp Business Overview
- 7.6.3 Labcorp Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.6.4 Labcorp Pharmacology Discovery Service Product Portfolio
- 7.6.5 Labcorp Recent Developments
- 7.7 BioDuro-Sundia
- 7.7.1 BioDuro-Sundia Company Information
- 7.7.2 BioDuro-Sundia Business Overview
- 7.7.3 BioDuro-Sundia Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.7.4 BioDuro-Sundia Pharmacology Discovery Service Product Portfolio
- 7.7.5 BioDuro-Sundia Recent Developments
- 7.8 Creative Biolabs
- 7.8.1 Creative Biolabs Company Information
- 7.8.2 Creative Biolabs Business Overview
- 7.8.3 Creative Biolabs Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.8.4 Creative Biolabs Pharmacology Discovery Service Product Portfolio
- 7.8.5 Creative Biolabs Recent Developments
- 7.9 BRF
- 7.9.1 BRF Company Information
- 7.9.2 BRF Business Overview
- 7.9.3 BRF Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.9.4 BRF Pharmacology Discovery Service Product Portfolio
- 7.9.5 BRF Recent Developments
- 7.10 WuXi AppTec
- 7.10.1 WuXi AppTec Company Information
- 7.10.2 WuXi AppTec Business Overview
- 7.10.3 WuXi AppTec Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.10.4 WuXi AppTec Pharmacology Discovery Service Product Portfolio
- 7.10.5 WuXi AppTec Recent Developments
- 7.11 Dalriada
- 7.11.1 Dalriada Company Information
- 7.11.2 Dalriada Business Overview
- 7.11.3 Dalriada Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.11.4 Dalriada Pharmacology Discovery Service Product Portfolio
- 7.11.5 Dalriada Recent Developments
- 7.12 Sygnature Discovery
- 7.12.1 Sygnature Discovery Company Information
- 7.12.2 Sygnature Discovery Business Overview
- 7.12.3 Sygnature Discovery Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.12.4 Sygnature Discovery Pharmacology Discovery Service Product Portfolio
- 7.12.5 Sygnature Discovery Recent Developments
- 7.13 Pharmaron
- 7.13.1 Pharmaron Company Information
- 7.13.2 Pharmaron Business Overview
- 7.13.3 Pharmaron Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.13.4 Pharmaron Pharmacology Discovery Service Product Portfolio
- 7.13.5 Pharmaron Recent Developments
- 7.14 ChemPartner
- 7.14.1 ChemPartner Company Information
- 7.14.2 ChemPartner Business Overview
- 7.14.3 ChemPartner Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.14.4 ChemPartner Pharmacology Discovery Service Product Portfolio
- 7.14.5 ChemPartner Recent Developments
- 7.15 NuChem Sciences Inc
- 7.15.1 NuChem Sciences Inc Company Information
- 7.15.2 NuChem Sciences Inc Business Overview
- 7.15.3 NuChem Sciences Inc Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.15.4 NuChem Sciences Inc Pharmacology Discovery Service Product Portfolio
- 7.15.5 NuChem Sciences Inc Recent Developments
- 7.16 Genscript ProBio
- 7.16.1 Genscript ProBio Company Information
- 7.16.2 Genscript ProBio Business Overview
- 7.16.3 Genscript ProBio Pharmacology Discovery Service Revenue and Gross Margin (2021-2026)
- 7.16.4 Genscript ProBio Pharmacology Discovery Service Product Portfolio
- 7.16.5 Genscript ProBio Recent Developments
8 North America
- 8.1 North America Pharmacology Discovery Service Revenue (2021-2032)
- 8.2 North America Pharmacology Discovery Service Revenue by Type (2021-2032)
- 8.2.1 North America Pharmacology Discovery Service Revenue by Type (2021-2026)
- 8.2.2 North America Pharmacology Discovery Service Revenue by Type (2027-2032)
- 8.3 North America Pharmacology Discovery Service Revenue Share by Type (2021-2032)
- 8.4 North America Pharmacology Discovery Service Revenue by Application (2021-2032)
- 8.4.1 North America Pharmacology Discovery Service Revenue by Application (2021-2026)
- 8.4.2 North America Pharmacology Discovery Service Revenue by Application (2027-2032)
- 8.5 North America Pharmacology Discovery Service Revenue Share by Application (2021-2032)
- 8.6 North America Pharmacology Discovery Service Revenue by Country
- 8.6.1 North America Pharmacology Discovery Service Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Pharmacology Discovery Service Revenue by Country (2021-2026)
- 8.6.3 North America Pharmacology Discovery Service Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Pharmacology Discovery Service Revenue (2021-2032)
- 9.2 Europe Pharmacology Discovery Service Revenue by Type (2021-2032)
- 9.2.1 Europe Pharmacology Discovery Service Revenue by Type (2021-2026)
- 9.2.2 Europe Pharmacology Discovery Service Revenue by Type (2027-2032)
- 9.3 Europe Pharmacology Discovery Service Revenue Share by Type (2021-2032)
- 9.4 Europe Pharmacology Discovery Service Revenue by Application (2021-2032)
- 9.4.1 Europe Pharmacology Discovery Service Revenue by Application (2021-2026)
- 9.4.2 Europe Pharmacology Discovery Service Revenue by Application (2027-2032)
- 9.5 Europe Pharmacology Discovery Service Revenue Share by Application (2021-2032)
- 9.6 Europe Pharmacology Discovery Service Revenue by Country
- 9.6.1 Europe Pharmacology Discovery Service Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Pharmacology Discovery Service Revenue by Country (2021-2026)
- 9.6.3 Europe Pharmacology Discovery Service Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Pharmacology Discovery Service Revenue (2021-2032)
- 10.2 China Pharmacology Discovery Service Revenue by Type (2021-2032)
- 10.2.1 China Pharmacology Discovery Service Revenue by Type (2021-2026)
- 10.2.2 China Pharmacology Discovery Service Revenue by Type (2027-2032)
- 10.3 China Pharmacology Discovery Service Revenue Share by Type (2021-2032)
- 10.4 China Pharmacology Discovery Service Revenue by Application (2021-2032)
- 10.4.1 China Pharmacology Discovery Service Revenue by Application (2021-2026)
- 10.4.2 China Pharmacology Discovery Service Revenue by Application (2027-2032)
- 10.5 China Pharmacology Discovery Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Pharmacology Discovery Service Revenue (2021-2032)
- 11.2 Asia Pharmacology Discovery Service Revenue by Type (2021-2032)
- 11.2.1 Asia Pharmacology Discovery Service Revenue by Type (2021-2026)
- 11.2.2 Asia Pharmacology Discovery Service Revenue by Type (2027-2032)
- 11.3 Asia Pharmacology Discovery Service Revenue Share by Type (2021-2032)
- 11.4 Asia Pharmacology Discovery Service Revenue by Application (2021-2032)
- 11.4.1 Asia Pharmacology Discovery Service Revenue by Application (2021-2026)
- 11.4.2 Asia Pharmacology Discovery Service Revenue by Application (2027-2032)
- 11.5 Asia Pharmacology Discovery Service Revenue Share by Application (2021-2032)
- 11.6 Asia Pharmacology Discovery Service Revenue by Country
- 11.6.1 Asia Pharmacology Discovery Service Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Pharmacology Discovery Service Revenue by Country (2021-2026)
- 11.6.3 Asia Pharmacology Discovery Service Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Pharmacology Discovery Service Revenue (2021-2032)
- 12.2 SAMEA Pharmacology Discovery Service Revenue by Type (2021-2032)
- 12.2.1 SAMEA Pharmacology Discovery Service Revenue by Type (2021-2026)
- 12.2.2 SAMEA Pharmacology Discovery Service Revenue by Type (2027-2032)
- 12.3 SAMEA Pharmacology Discovery Service Revenue Share by Type (2021-2032)
- 12.4 SAMEA Pharmacology Discovery Service Revenue by Application (2021-2032)
- 12.4.1 SAMEA Pharmacology Discovery Service Revenue by Application (2021-2026)
- 12.4.2 SAMEA Pharmacology Discovery Service Revenue by Application (2027-2032)
- 12.5 SAMEA Pharmacology Discovery Service Revenue Share by Application (2021-2032)
- 12.6 SAMEA Pharmacology Discovery Service Revenue by Country
- 12.6.1 SAMEA Pharmacology Discovery Service Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Pharmacology Discovery Service Revenue by Country (2021-2026)
- 12.6.3 SAMEA Pharmacology Discovery Service Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst